Dr. Sreus Naidu is a healthcare leader with over fifteen years of experience in scientific research, regulatory science, and therapeutic innovation. Holding a Doctorate of Pharmacy and a Master’s in Regulatory Science from the University of Southern California (USC), he has spearheaded multiple research initiatives, clinical studies, and the development of advanced health technologies for both human and veterinary medicine. His work has consistently demonstrated measurable improvements in patient outcomes through precision-based therapies.
As CEO of bioQuad Life Sciences and Bio-Rep Animal Health, Dr. Naidu has directed the global launch of patented health solutions targeting critical physiological systems, including immune, gastrointestinal, cardiovascular, neurocognitive, and musculoskeletal health. His leadership has driven the successful commercialization of clinically validated products that are trusted by healthcare providers and patients worldwide.
Dr. Naidu’s expertise extends to the development of patented bioactive formulations designed to optimize cellular function, restore systemic balance, and support recovery in various clinical settings. His pioneering research has resulted in multiple core patents, including compositions that enhance host defense mechanisms, regulate inflammatory responses, and promote targeted health benefits.
His recent research focuses on the pathophysiology of Long COVID, emphasizing post-viral recovery and the establishment of evidence-based clinical management guidelines. His findings have been published in high-impact, peer-reviewed journals, including Nature, underscoring his commitment to advancing clinical science and improving patient care. Dr. Naidu’s contributions have directly influenced patient management protocols and clinical best practices, addressing critical public health challenges.